Germline Genetic Features of Young Individuals With Colorectal Cancer

Gastroenterology

Volumn 154, Issue 4, 2018, Pages 897-905.e1

  Stoffel, Elena M ^a   Koeppe, Erika ^a   Everett, Jessica ^a   Ulintz, Peter ^a   Kiel, Mark ^b   Osborne, Jenae ^a   Williams, Linford ^c   Hanson, Kristen ^a   Gruber, Stephen B ^d   Rozek, Laura S ^e  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Genomenon Inc   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

APC; FDR; NGS; Risk

Indexed keywords

APC PROTEIN; BONE MORPHOGENETIC PROTEIN RECEPTOR 1A; BRCA1 PROTEIN; CHECKPOINT KINASE 2; DNA; DNA GLYCOSYLASE MUTY; POLE PROTEIN; PROTEIN P53; SMAD4 PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG; TUMOR MARKER;

ADOLESCENT; ADULT; ARTICLE; CANCER CENTER; CANCER GENETICS; CANCER LOCALIZATION; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SUSCEPTIBILITY; CLINICAL EVALUATION; COLORECTAL CANCER; DNA SEQUENCE; FAMILIAL ADENOMATOUS POLYPOSIS; FAMILY HISTORY; FEMALE; FIRST-DEGREE RELATIVE; GENETIC ASSOCIATION; GENETIC COUNSELING; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SCREENING; GERMLINE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HEREDITARY TUMOR SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL GENETICS; MEDICAL HISTORY; MEDICAL RECORD REVIEW; MISMATCH REPAIR; MULTIGENE FAMILY; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; COLORECTAL TUMOR; DNA MUTATIONAL ANALYSIS; GENETICS; HEREDITY; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; ONSET AGE; PEDIGREE; PHENOTYPE; PREDICTIVE VALUE; PROCEDURES; RISK FACTOR; TERTIARY CARE CENTER; YOUNG ADULT;

ADOLESCENT; ADULT; AGE OF ONSET; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HEREDITY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; PEDIGREE; PHENOTYPE; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; TERTIARY CARE CENTERS; YOUNG ADULT;

EID: 85043295931     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2017.11.004     Document Type: Article

References (47)

1. Edwards, B.K., Ward, E., Kohler, B.A., et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116 (2010), 544–573.
2. Meyer, J.E., Narang, T., Schnoll-Sussman, F.H., et al. Increasing incidence of rectal cancer in patients aged younger than 40 years: an analysis of the surveillance, epidemiology, and end results database. Cancer 116 (2010), 4354–4359.
3. Siegel, R.L., Jemal, A., Ward, E.M., Increase in incidence of colorectal cancer among young men and women in the United States. Cancer Epidemiol Biomarkers Prev 18 (2009), 1695–1698.
4. Bailey, C.E., Hu, C.Y., You, Y.N., et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975–2010. JAMA Surg 150 (2015), 17–22.
5. Siegel, R.L., Fedewa, S.A., Anderson, W.F., et al. Colorectal cancer incidence patterns in the United States, 1974–2013. J Natl Cancer Inst, 109(8), 2017.
6. Abdelsattar, Z.M., Wong, S.L., Regenbogen, S.E., et al. Colorectal cancer outcomes and treatment patterns in patients too young for average-risk screening. Cancer 122 (2016), 929–934.
7. Levin, B., Lieberman, D.A., McFarland, B., et al., American Cancer Society Colorectal Cancer Advisory Group, US Multi-Society Task Force, American College of Radiology Colon Cancer Committee. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 134 (2008), 1570–1595.
8. Jasperson, K.W., Tuohy, T.M., Neklason, D.W., Burt, R.W., Hereditary and familial colon cancer. Gastroenterology 138 (2010), 2044–2058.
9. Hampel, H., Frankel, W.L., Martin, E., et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 26 (2008), 5783–5788.
10. Moreira, L., Balaguer, F., Lindor, N., et al. Identification of Lynch syndrome among patients with colorectal cancer. JAMA 308 (2012), 1555–1565.
11. Aaltonen, L.A., Salovaara, R., Kristo, P., et al. Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. N Engl J Med 338 (1998), 1481–1487.
12. Yurgelun, M.B., Kulke, M.H., Fuchs, C.S., et al. Cancer susceptibility gene mutations in individuals with colorectal cancer. J Clin Oncol 35 (2017), 1086–1095.
13. Evaluation of Genomic Applications in Prevention Working Group. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 11 (2009), 35–41.
14. Grover, S., Kastrinos, F., Steyerberg, E.W., et al. Prevalence and phenotypes of APC and MUTYH mutations in patients with multiple colorectal adenomas. JAMA 308 (2012), 485–492.
15. Syngal, S., Brand, R.E., Church, J.M., et al., American College of Gastroenterology. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 110 (2015), 223–262 quiz 63.
16. Giardiello, F.M., Allen, J.I., Axilbund, J.E., et al., Cancer US Multi-Society Task Force on Colorectal Cancer. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on colorectal cancer. Gastroenterology 147 (2014), 502–526.
17. National Comprehensive Cancer Network. Genetic/familial high risk assessment: breast and/or ovarian and colorectal. NCCN Clinical Practice Guidelines in Oncology. 2016; v. 2.2017. Available at: www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf.
18. Broderick, P., Dobbins, S.E., Chubb, D., et al. Validation of recently proposed colorectal cancer susceptibility gene variants in an analysis of families and patients—a systematic review. Gastroenterology 152 (2017), 75–77.e4.
19. Yurgelun, M.B., Allen, B., Kaldate, R.R., et al. Identification of a variety of mutations in cancer predisposition genes in patients with suspected Lynch syndrome. Gastroenterology 149 (2015), 604–613.e20.
20. Walsh, T., Casadei, S., Lee, M.K., et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A 108 (2011), 18032–18037.
21. Kurian, A.W., Hare, E.E., Mills, M.A., et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol 32 (2014), 2001–2009.
22. Cragun, D., Radford, C., Dolinsky, J.S., et al. Panel-based testing for inherited colorectal cancer: a descriptive study of clinical testing performed by a US laboratory. Clin Genet 86 (2014), 510–520.
23. Limburg, P.J., Harmsen, W.S., Chen, H.H., et al. Prevalence of alterations in DNA mismatch repair genes in patients with young-onset colorectal cancer. Clin Gastroenterol Hepatol 9 (2011), 497–502.
24. Giraldez, M.D., Balaguer, F., Bujanda, L., et al. MSH6 and MUTYH deficiency is a frequent event in early-onset colorectal cancer. Clin Cancer Res 16 (2010), 5402–5413.
25. Chang, D.T., Pai, R.K., Rybicki, L.A., et al. Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. Mod Pathol 25 (2012), 1128–1139.
26. Terdiman, J.P., Levin, T.R., Allen, B.A., et al. Hereditary nonpolyposis colorectal cancer in young colorectal cancer patients: high-risk clinic versus population-based registry. Gastroenterology 122 (2002), 940–947.
27. Goel, A., Nagasaka, T., Spiegel, J., et al. Low frequency of Lynch syndrome among young patients with non-familial colorectal cancer. Clin Gastroenterol Hepatol 8 (2010), 966–971.
28. Chen, S., Wang, W., Lee, S., et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA 296 (2006), 1479–1487.
29. Mork, M.E., You, Y.N., Ying, J., et al. High prevalence of hereditary cancer syndromes in adolescents and young adults with colorectal cancer. J Clin Oncol 33 (2015), 3544–3549.
30. Pearlman, R., Frankel, W.L., Swanson, B., Ohio Colorectal Cancer Prevention Initiative Study Group. Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer. JAMA Oncol 3 (2017), 464–471.
31. Richards, S., Aziz, N., Bale, S., et al., ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17 (2015), 405–424.
32. Kastrinos, F., Steyerberg, E.W., Mercado, R., et al. The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology 140 (2011), 73–81.
33. Yurgelun, M.B., Masciari, S., Joshi, V.A., et al., Colon Cancer Family Registry. Germline TP53 mutations in patients with early-onset colorectal cancer in the Colon Cancer Family Registry. JAMA Oncol 1 (2015), 214–221.
34. Pujol, P., Lyonnet, D.S., Frebourg, T., et al. Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests. Breast Cancer Res Treat 141 (2013), 135–144.
35. Idos G KA, McDonnel K, et al. The GI gap in genetic testing for inherited susceptibility to cancer. American College of Gastroenterology Annual Meeting, Abstract P159. [Abstract]. 2015.
36. National Comprehensive Cancer Network. Genetic/familial high risk assessment: breast and ovarian. NCCN Clinical Practice Guidelines in Oncology. 2016; v. 2.2016. Available at: www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf.
37. Robson, M.E., Bradbury, A.R., Arun, B., et al. American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. J Clin Oncol 33 (2015), 3660–3667.
38. Gallego, C.J., Shirts, B.H., Bennette, C.S., et al. Next-generation sequencing panels for the diagnosis of colorectal cancer and polyposis syndromes: a cost-effectiveness analysis. J Clin Oncol 33 (2015), 2084–2091.
39. Guindalini, R.S., Win, A.K., Gulden, C., et al. Mutation spectrum and risk of colorectal cancer in African American families with Lynch syndrome. Gastroenterology 149 (2015), 1446–1453.
40. Siegel, R.L., Miller, K.D., Jemal, A., Colorectal cancer mortality rates in adults aged 20 to 54 years in the United States, 1970–2014. JAMA 318 (2017), 572–574.
41. Luba, D.G., DiSario, J.A., Rock, C., et al. Community practice implementation of a self-administered version of PREMM1,2,6 to assess risk for Lynch syndrome. Clin Gastroenterol Hepatol 16 (2018), 49–58.
42. Kastrinos, F., Uno, H., Ukaegbu, C., et al. Development and validation of the PREMM5 model for comprehensive risk assessment of Lynch syndrome. J Clin Oncol 35 (2017), 2165–2172.
43. Haraldsdottir, S., Rafnar, T., Frankel, W.L., et al. Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2. Nat Commun, 8, 2017, 14755.
44. Goodenberger, M.L., Thomas, B.C., Riegert-Johnson, D., et al. PMS2 monoallelic mutation carriers: the known unknown. Genet Med 18 (2016), 13–19.
45. Win, A.K., Jenkins, M.A., Dowty, J.G., et al. Prevalence and penetrance of major genes and polygenes for colorectal cancer. Cancer Epidemiol Biomarkers Prev 26 (2017), 404–412.
46. Ahnen, D.J., Wade, S.W., Jones, W.F., et al. The increasing incidence of young-onset colorectal cancer: a call to action. Mayo Clin Proc 89 (2014), 216–224.
47. Yurgelun, M.B., Boland, C.R., “New” cancer genes and inherited colorectal cancer risk: caveat emptor. Gastroenterology 152 (2017), 12–13.